Mobility and satisfaction with a microprocessor-controlled knee in moderately active amputees: A multi-centric randomized crossover trial.


With Kenevo compared to NMPK:

- **Risk of falling reduced**
  - Timed Up and Go (TUG) test: clinically and statistically significant reduction of 12.9% (p=0.001)*
  - Number of falls during last 30 days of observation:
    - 6 falls with NMPK (4 related to NMPK), 1 fall with Kenevo (none related to Kenevo; difference in falls did not reach statistical significance)*

- **Mobility significantly increased**
  - Locomotor Capability Index (L CI-5) global mean increased by 7.4% (p=0.006)*

- **Satisfaction and domains of quality of life significantly increased**
  - QUEST 2.0 score increased by 15.2% (p=0.002)*
  - Significant increase in the SF-36 domains mental component score (p=0.01), physical activity (p=0.04), limitations related to physical health (p=0.005), mental health (p=0.009) and limitations related to mental health (p=0.04).*

* Based on Intent-to-Treat (ITT) Analysis
Population

Subjects: 33 unilateral transfemoral, 2 unilateral knee disarticulated amputees
Previous prosthesis: NMPK
Amputation causes: 57% vascular, 11% diabetic vascular, 23% trauma, 11% tumour, 9% infection
Mean age: 65.6 ± 10.1 years
Mean time since amputation: 61.4 ± 85.5 months

Study Design

Interventional randomized cross-over study:

Data was analyzed both by intent-to-treat (ITT) with the population mentioned above (for ITT analysis n=30 after 5 participants decided not to continue study or did not qualify for first assessment) as well as per-protocol (PP, n=27 after 3 participants were not able to use the prosthesis as described in the protocol).

Results

<table>
<thead>
<tr>
<th>Category</th>
<th>Outcomes</th>
<th>Results for Kenevo</th>
<th>Sig.*</th>
</tr>
</thead>
<tbody>
<tr>
<td>Safety</td>
<td>TUG (Timed Up and Go Test) (ITT)</td>
<td>Participants needed 12.9% less time to complete the TUG test.</td>
<td>++</td>
</tr>
<tr>
<td></td>
<td>TUG (Timed Up and Go Test) (PP)</td>
<td>Participants needed 16% less time to complete the TUG test.</td>
<td>++</td>
</tr>
<tr>
<td></td>
<td>Number of falls (ITT)</td>
<td>Total number of falls during last 30 days of observation: 6 falls with NMPKs, 1 fall with Kenevo. Falls related to the knee: 4 with NMPK, 0 with Kenevo.</td>
<td>0</td>
</tr>
<tr>
<td></td>
<td>Number of falls (PP)</td>
<td>Total number of falls during last 30 days of observation: 3 falls with NMPKs, 1 fall with Kenevo. Falls related to the knee: 2 with NMPK, 0 with Kenevo.</td>
<td>0</td>
</tr>
<tr>
<td>Activity, Mobility, Activities of Daily Living (ADLs)</td>
<td>LCI-5 (Locomotor Capability Index) (ITT)</td>
<td>The LCI-5 score was increased by 7.4%. Basic activities score: + 8.2%</td>
<td>++</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Advanced activities score: + 6.6%</td>
<td>0</td>
</tr>
<tr>
<td></td>
<td>LCI-5 (Locomotor Capability Index) (PP)</td>
<td>The LCI-5 score was increased by 5.6%. Basic activities score: + 6.3%</td>
<td>++</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Advanced activities score: + 4.4%</td>
<td>0</td>
</tr>
</tbody>
</table>
**Category** | **Outcomes** | **Results for Kenevo** | **Sig.***
---|---|---|---
Preference, Satisfaction, Quality of Life (QoL) | Number of walking aids (ITT, PP) | The number of walking aids needed did not change significantly. | 0

| QUEST 2.0 (Quebec User Evaluation of Satisfaction with assistive Technology) (ITT) | Global score significantly increased by 15.2%. Technology score: +15.5% Service score: +8.2% | ++
| QUEST 2.0 (Quebec User Evaluation of Satisfaction with assistive Technology) (PP) | Global score significantly increased by 17%. Technology score: +13.3% Service score: +4% | ++

SF-36 (ITT) | All subscores of SF-36 increased, indicating a higher quality of life. | +

| | The changes in the domains mental component score (+11.3%) physical activity (+14.2%), limitations related to physical health (+35.7%), mental health (+17.1%) and limitations related to mental health (25%) were significant. | ++

SF-36 (PP) | All subscores of SF-36 increased, indicating a higher quality of life. | +

| | The changes in the domains mental component score (+11.5%), limitations related to physical health (+33.4%) and mental health (+16.7%) were significant. | ++

* no difference (0), positive trend (+), negative trend (−), significant (++/−−), not applicable (n.a.)

**Author’s Conclusion**

“Recent studies suggested that MPKs could be useful for amputees with moderate activity level. We compared the efficiency of a MPK (Kenevo, Otto Bock) and NMPKs for these individuals in a multi-centric randomized crossover study, which provided a high level of evidence. Dynamic balance and functional mobility were improved with the MPK, as were satisfaction and quality of life on the MCS of the SF-36v2. The incidence of falls did not differ with use of the 2 devices. Thus, all individuals with transfemoral amputation or knee disarticulation, regardless of their mobility grade, can be provided with appropriate prostheses. […] In conclusion, MPKs explicitly tailored to the specific needs of this vulnerable population should be considered a viable therapeutic option to increase mobility and participation. Once other MPKs dedicated to moderately active persons are available on the market, comparisons with the Kenevo will be necessary for clinicians and health authorities to provide accurate recommendations and guidelines in the choice of the device.”

© 2018, Otto Bock HealthCare Products GmbH (“Otto Bock”), All Rights Reserved. This article contains copyrighted material. Wherever possible we give full recognition to the authors. We believe this constitutes a ‘fair use’ of any such copyrighted material according to Title 17 U.S.C. Section 107 of US Copyright Law. If you wish to use copyrighted material from this site for purposes of your own that go beyond ‘fair use’, you must obtain permission from the copyright owner. All trademarks, copyrights, or other intellectual property used or referenced herein are the property of their respective owners. The information presented here is in summary form only and intended to provide broad knowledge of products offered. You should consult your physician before purchasing any product(s). Otto Bock disclaims any liability related from medical decisions made based on this article summary.